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Abstract
Background: The effects of sorafenib in the treatment of advanced renal cell carcinoma (RCC) have been confirmed in
an international collaborative phase III trial. This study aims to confirm similar efficacy and treatment-induced toxicities
of sorafenib in the treatment of metastatic RCC in ethnic Chinese patients.
Methods: Ninety-eight consecutive and non-selected patients with pathologically confirmed metastatic RCC were
treated according to an institutional treatment protocol. All patients were treated with 400 mg of sorafenib orally twice
daily on a continuous basis until disease progression or intolerance to treatment occurred. Dose reduction to 400 mg
once daily was required if grade 3 or 4 toxicities occurred. All patients except for 7 received nephrectomy in the course
of their disease. All patients were assessed for tumor response, progression-free survival (PFS), overall survival (OS), and
treatment-induced toxicities.
Results: The median follow-up time was 76 weeks (range 2–296 weeks) for the entire group of patients. Radiologically
confirmed complete response (CR), partial response (PR), stable disease (SD) of more than 4 months, and disease
progression as best objective responses were observed in 1 (1%), 23 (23.5%), 62 (63.3%), and 12 (12.2%) patients,
respectively. The tumor control rate (CR+PR+SD of >4 months) was 87.8%. The 1-year estimated PFS and OS were
58.4% and 64.6%, respectively. The median progression-free survival (PFS) time was 60 weeks (95% CI 41–79); and the
median overall survival (OS) time was not reached with a follow-up of 76 weeks. Reduction of sorafenib dose was
required in 26 patients who developed grade 3 or 4 treatment-cause adverse-effects. An additional 9 patients
discontinued sorafenib treatment due to severe adverse-effects. No grade 5 toxicity occurred.
Multivariate analysis revealed that independent predictive factors for tumor response to sorafenib treatment included
ECOG status, presence of lymph node metastasis, and nephrectomy prior to the development of metastasis.
Conclusion: Sorafenib produced an 87.8% disease control rate for metastatic renal cell carcinoma in Chinese patients,
with acceptable rates of toxicity. The medication dosed at 400 mg twice daily is both efficacious and safe in the treatment
of metastatic renal cell carcinoma in Chinese patients.
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Background
Renal cell carcinoma (RCC) is the most commonly diag-
nosed malignancy of the kidney. Although surgery is cur-
ative for localized diseases, approximately 30% of
patients present with distant metastasis at the time of
diagnosis [1]. In addition, more than 25% of patients with
locally advanced RCC develop distant metastasis after cur-
ative resection. As RCC is highly resistant to chemother-
apy, and its response to cytokine therapy including high-
dose interleukin-2 (IL-2) and/or interferon-alfa is less
than 20% [2,3], the outcome for patients with metastatic
disease is dismal: The 5-year overall survival rate despite
systemic treatment is less than 10% [4]. Effective systemic
treatment for metastatic RCC is clearly needed.
Sorafenib (BAY 43-9006) is a novel agent originally devel-
oped as a Raf Kinase inhibitor with a potent effect on C-
Raf. Its multi-targeting effects were lately discovered, and
in addition to C-Raf, sorafenib also demonstrated effects
against B-Raf, vascular endothelial growth factor receptor-
2 (VEGFR2), platelet-derived growth factor receptor
(PDGFR), Fms-like tyrosine kinase-3 (Flt-3), and stem-cell
growth factor (c-KIT) [5]. The efficacy of sorafenib on RCC
has been confirmed in both phase II and phase III trials,
which had resulted in the approval of its use as a second-
line treatment in metastatic disease [6,7]. The progres-
sion-free survival (PFS) of patients with advanced RCC
reached 5.5 months after sorafenib treatment, as com-
pared to 2.8 months for those received placebo. Sorafenib
was approved in most Asian countries/regions including
China for metastatic RCC based on these results.
The difference in the expression of tumor markers and
molecular features of patients of different ethnic group in
a number of malignancies such as lung cancer, prostate
cancer, breast cancer, and astrocytoma have been well
documented [8-12]. It has also been demonstrated that
the RCC diagnosed in different ethnic groups may host
different characteristics and behaviors [13]. Although the
nature of these variations and their potentially associated
molecular basis have not been addressed, it is reasonable
to postulate that and the efficacy of sorafenib on advanced
RCC may vary in patients of different ethnic background.
However, most of the clinical trials of sorafenib for meta-
static RCC reported so far included few patients of Asian
origin, and the efficacy of sorafenib on RCC diagnosed in
Asian patients particularly Chinese has never been
reported. The aim of this study is to document the multi-
center experience in a relatively large group of Chinese
patients with metastatic RCC treated with sorafenib using
a protocolized regimen. Special emphasis was placed on
the patients' overall and progression-free survivals and
treatment-induced toxicities.
Methods
Patients and Staging Evaluation
Between March 2006 and March 2008, 98 consecutive
and non-selected patients who were diagnosed with met-
astatic RCC were treated with sorafenib according to an
institutional treatment protocol jointly developed by the
Departments of Urology of the Fudan University Shang-
hai Cancer Center and Renji Hospital of Shanghai Jiao
Tong University School of Medicine, Shanghai, China,
based on the treatment recommendation approved by the
U.S. Food and Drug Administration (FDA) for metastatic
RCC. The treatment protocol was approved by the institu-
tional review boards of both participating hospitals. All
98 patients had pathologically confirmed RCC from their
primary or metastatic site(s), and their tumors were staged
according to the AJCC (2002) cancer staging classification
as stage IV [14]. Patients with central nervous system
metastasis were not eligible to the treatment protocol.
Other criteria of exclusion into the treatment protocol
included age < 18 or > 80 years, ECOG performance status
>3, and life expectancy of less than 3 months.
Pretreatment evaluation consisted of a complete history
and physical examination, complete blood count, liver
and renal function tests, CT scan of the chest, CT scan or
MRI of the abdomen and pelvis, and total body bone
scan. FDG-PET or PET/CT scan were optional.
Patient's characteristics are listed in Table 1.
Treatment
Informed consent was required and obtained from all
patients prior to the initiation of treatment. All patients
received 400 mg of sorafenib orally twice daily, spaced 12
hours apart, on continuous basis. Dose modification to
400 mg once daily was permitted if grade 3 or 4 hemato-
logic toxicity, skin toxicity, hypertension, and/or hepatic
dysfunction defined by the NCI-CTCAE 3.0 occurred. The
treatment continued until disease progress or intolerance
to the treatment occurred. Among all 98 patients, 43
patients initiated their treatment with sorafenib only and
16 received sorafenib with interferon as their first-line
therapy, and 39 patients had received sorafenib after they
had failed interleukin- and/or interferon-based therapy.
A total of 91 patients had nephrectomy during the course
of their disease. Sixty-six patients underwent nephrectomy
as part of their definitive treatment for the primary disease
prior to the development of metastasis, and 25 patients
initially diagnosed with metastatic RCC received nephrec-
tomy for palliative treatment. Seven patients who had
metastatic RCC as their initial diagnosis did not receive
nephrectomy mostly due to patients' preference.BMC Cancer 2009, 9:249 http://www.biomedcentral.com/1471-2407/9/249
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Follow-up
All patients were required to be evaluated weekly during
their treatment with sorafenib by their attending urolo-
gists. Patients also had to be followed-up by their attend-
ing urologists every 2 months after the termination of
their treatment, if intolerance to the treatment occurred.
As a requirement of the protocol, each follow-up session
included a complete history and physical examination,
routine laboratory tests including CBC, serum electro-
lytes, liver and renal function tests. CT scan of the chest,
abdomen, and pelvis were performed on monthly basis
during the treatment, and at every follow-up visit after the
termination of the treatment. Tumor response was meas-
ured starting at one month after the initiation of the treat-
ment using the RECIST criteria. The radiological responses
were evaluated by both diagnostic radiologist(s) inde-
pendent to this study and verified by investigators.
The adverse-effects secondary to the treatment were evalu-
ated at each visit during and after the treatment, and were
recorded according to the Common terminology criteria
for adverse events v3.0 (CTCAE) of the National Cancer
Institute.
Data Analysis
Disease control rate was defined as the proportion of
patient who achieved stable disease (SD) for more than 4
months, partial response (PR), and complete response
(CR) in the entire cohort of 98 cases. Progression-free sur-
vival (PFS) time was measured from the date of the initia-
tion of sorafenib treatment until documented
radiologically confirmed disease progression or death of
patient, whichever is earlier. The duration of overall sur-
vival (OS) was calculated from the date of the initiation of
sorafenib treatment until death or until the date of the last
follow-up visit for patients still alive. Both PFS and OS
duration were calculated by the Kaplan-Meier method
[15].
Results
Treatment outcome
The median follow-up time was 76 weeks (range 2 to 296
weeks) for the entire group of 98 patients. Radiologically
confirmed CR, PR, stable disease (of more than 4
months), and disease progression as best objective
responses were observed in 1 (1%), 23 (23.5%), 62
(63.3%), and 12 (12.2%) patients, respectively, and the
overall disease control rate were 87.8%. The 1-year esti-
mated PFS and OS were 58.4% and 64.6%, respectively
(Figure 1 and 2). The median progression-free survival
(PFS) was 60 weeks (95% CI 41–79), and the median
overall survival (OS) was not reached at the time of this
analysis. No statistical differences were observed in OS or
PFS for patients received sorafenib as their first-line treat-
ment or after cytokine therapy.
At the time of this analysis, 29 patients (29.5%) had
deceased: 24 patients died of disease progression, 4
patients died of intercurrent diseases (heart or pulmonary
conditions) that were not associated with their RCC or
treatment, and 1 patient died of traffic accident.
Adverse-Effects
All patients experienced adverse-effects of some sorts;
however, the studied treatment protocol was well toler-
ated and most patients experienced grade 1 or 2 toxicities
(Table 2). A total of 26 (26.5%) patients required dose
reduction due to grade 3 or 4 adverse-effects, and 9 (9.2%)
discontinued their treatment due to severe adverse-effects.
Table 1: Patients' characteristics.
Characteristic No. patients (%)
Age, y
>= 60 26 (26.5)
<60 72 (73.5)
Sex
Male 73 (74.5)
Female 25 (25.5)
T-classification at initial diagnosis
T1 19 (19.4)
T2 30 (30.6)
T3 42 (42.9)
T4 7 (7.1)
AJCC staging group at initial diagnosis
I 11 (11.2)
II 24 (24.5)
III 18 (18.4)
IV 45 (45.9)
Fuhrman grade
1 4 (4.1)
2 49 (50.0)
3 39 (39.8)
4 6 (6.1)
Histology
Predominant clear cell 87 (88.8)
Non-clear cell 11 (11.2)
Sites of metastatic diseases
Lung 70 (71.4)
Liver 10 (10.2)
Bone 18 (18.4)
Lymph node 24 (24.5)
Adrenal gland 12 (12.2)
Other 12 (12.2)
Number of metastatic foci
1 20 (20.4)
2 29 (29.6)
3 21 (21.4)
>= 4 28 (28.6)
ECOG performance status
0 56 (57.1)
1 37 (37.8)
2 4 (4.1)
3 1 (1.0)BMC Cancer 2009, 9:249 http://www.biomedcentral.com/1471-2407/9/249
Page 4 of 8
(page number not for citation purposes)
The remaining 63(64.3%) patients tolerated and contin-
ued their treatment with standard dose of sorafenib at the
time of this analysis or until disease progression. The most
commonly observed severe toxicity was hand-foot syn-
drome and anemia, and both were seen in 13 (13.3%)
patients. Treatment-induced grade V toxicity was not
observed.
Table 2 detail the cumulative incidence of toxicities
observed in the entire group of patients.
Predictive Factors of Response to Sorafenib
The value of various potential factors including patients'
age, gender, ECOG status before treatment, pathologic
type, tumor differentiation, presence of lymphvascualr
invasion, number of metastatic foci (1–3 versus >3), and
timing of sorafenib treatment (first-line versus second-
line) were evaluated in both uni- and multivariate analy-
ses for predicting the response to sorafenib. Univariate
analyses indicated that pretreatment ECOG status, pres-
ence of lymph node metastasis (N+), number of meta-
static foci (1–3 versus >3), and nephrectomy as primary
treatment prior to the development of distant metastasis
were significant predictive factors of tumor control (CR,
PR, or stable disease of more than 4 months) to sorafenib
treatment. However, only favorable pretreatment ECOG
status, N+, and the use of nephrectomy were statistically
significant for predicting the disease control on multivar-
iate analyses (Table 3).
Discussion
Renal cell carcinoma (RCC) is the predominant form of
kidney cancer, and systemic therapy using cytokine or
cytotoxic agents provides limited effects to RCC with dis-
tant metastasis. An international collaborative study has
confirmed that targeted therapy agent sorafenib (BAY 43-
9006) was effective in the treatment of metastatic RCC
and could provide a significant improvement in the pro-
gression-free survival (PFS) with acceptable adverse-effect
profile [7]. In the current study, we have demonstrated
that sorafenib is equally effective in the treatment of met-
astatic RCC diagnosed in patients of Chinese ethnic back-
ground. The median progression-free survival time was 60
weeks, and overall survival time was not reached after a
follow-up of 76 weeks. In addition, sorafenib was well tol-
erated by Chinese patients with metastatic RCC: Grade 3
and 4 toxicities were observed in 35.7% patients, and only
9 (9.2%) patients terminated their treatment due to
adverse-effects. Furthermore, disease control, which was
defined as radiologically confirmed CR, PR, and stable
disease of more than 4 months, was achieved in 87.8% of
patients. Results of multivariate analysis revealed that
presence of lymph node metastasis, better ECOG status,
and use of nephrectomy for definitive treatment prior to
the development of metastatic disease were significant
factors for predicting disease control to sorafenib treat-
ment.
Sorafenib is a multikinase inhibitor and has potent effects
on c-Raf, b-Raf, VEGFR-2, and PDGFR, and it is postulated
that the effect of sorafenib on RCC is closely associated
with its effect on VEGF receptor [16]. The exact mecha-
nism of its effect on RCC is largely unknown, but its effi-
cacy on metastatic RCC as a second-line treatment has
been proven. Although variations in the expression of
VEGF receptors and other potential treatment targets of
RCC in patients of different ethnic background have not
been reported, race-dependent variation in other molecu-
lar targets such as epidermal growth factor (EGF) is well
known. For example, gefitinib is a tyrosine kinase inhibi-
tor that has been actively utilized in the treatment of non-
small-cell lung cancer (NSCLC) particularly in Asia. Its
efficacy in NSCLC has been repeatedly demonstrated in
Asian patients; however, the results of an international
collaborative study did not confirm such findings [17],
and the medication was not approved for the treatment of
NSCLC in the United States by the Food and Drug Admin-
istration. It was lately discovered that the efficacy of gefit-
inib was associated with EGF mutations, which is
significantly more prevalent in Asian patients with
NSCLC, particularly adenocarcinoma [18,19], thus
explained the discrepancy in the outcome of NSCLC after
gefitinib treatment. Similar findings have been reported in
the expression of other molecular targets for treatment in
various types of malignancies such as breast cancer diag-
nosed in patients with different ethnic background [8-12].
In the case of renal cell carcinoma, it has been demon-
strated that the malignancy diagnosed in various ethnic
groups had different clinical characteristics: The present-
ing symptoms, the course of disease, and the outcome
after standard treatment varied significantly between
Progression-free survival of patients Figure 1
Progression-free survival of patients.BMC Cancer 2009, 9:249 http://www.biomedcentral.com/1471-2407/9/249
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patients of Caucasian, Hispanic, African-American, and
Asian backgrounds [13]. Whether these differences were
induced by any variations at molecular level remained
unknown; however, it is reasonable to postulate that the
differences in the tumor cell at the genetic level play an
important role in determine the differences in the pheno-
type of the disease, and question whether sorafenib pro-
vides similar level of efficacy in Asian patients with
metastatic RCC. The results of the current study revealed
that sorafenib produced a median progression-free sur-
vival time of 60 weeks and was well tolerated. As treat-
ment options for metastatic RCC is relatively limited, and
response of RCC to chemotherapy or immunotherapy is
suboptimal, our favorable results which confirmed the
efficacy of sorafenib in Asian particular Chinese patients
supported practice change in the treatment of metastatic
RCC.
Reports on the efficacy of sorafenib in non-Caucasian
patients with advanced RCC have been limited. In a non-
planned subgroup analysis of 15 Spanish patients accrued
in the TARGET study (7 on sorafenib arm and 8 on pla-
cebo arm), a trend of improved PFS was demonstrated,
and the author concluded that the efficacy and toxicity of
Spanish patients follow the trend observed for the overall
international population [20]. In addition, a phase II clin-
ical trial from Japan confirmed the efficacy of sorafenib in
Japanese patients with advanced RCC who had nephrec-
tomy and had failed cytokine-containing therapy. The
study focused on the response to treatment as well as PFS,
and reported partial response and stable disease (of more
than 4 weeks) rates of 14.7% and 72.1%, respectively,
with a total disease control rate of 86.8%. The PFS of the
entire group of patients was 224 days (32 weeks) [21]. The
overall disease control rate in the current series was
87.8%, which was similar to the finding of the Japanese
study. In addition, the median PFS of 60 weeks from our
series also provided a reasonable support to the Japanese
data and the use of sorafenib in Chinese patients with
advanced RCC.
Despite of the prospective nature of our treatment proto-
col and its favorable results, several important issues need
to be addressed in the current study. First of all, the cur-
rent study is a single arm series aimed to study the efficacy
of sorafenib in the treatment of metastatic RCC in Chinese
patients. Although all patients were treated with sorafenib
according to a prospectively designed regimen, the study
was not designed as a prospective phase II trial. Sorafenib
was approved by the State Food and Drug Administration
(SFDA) of China for its use in patients with advanced
RCC, further investigation for a proven medication in the
form of a prospective phase II or randomized clinical trials
would not be easily acceptable by patients with a terminal
disease, considering sorafenib was the only approved
effective treatment for advanced RCC in China when we
initiated this study.
In addition, a substantial portion of the patients our series
were cytokine naïve and received sorafenib as the first-line
treatment. While phase II and III trials have repeated dem-
onstrated the effect of sorafenib on advanced renal cell
carcinoma, treatment in the majority of previously
reported trials were delivered after the failure of cytokine
treatment. Although no significant difference was found
among patients received first-versus second-line treatment
in our trial, the small number of both subgroups pre-
cluded a statistically meaningful comparison. In addition,
the mixed timing of sorafenib use might adversely affect
the uniformity of the treatment outcome. The effect of sor-
afenib as a first-line treatment in advanced RCC compar-
ing to conventional therapy, i.e., nephrectomy followed
by cytokine therapy has not been confirmed. And whether
a progression-free survival or overall survival benefit can
be further provided by early use of sorafenib therapy par-
ticularly in Chinese patients remains unknown. Thirdly,
concurrent therapy using cytokine with sorafenib was not
prohibited in the protocol. Among all patients received
sorafenib as the first-line treatment, 16 patients received
concurrent cytokine treatment. Results from a phase I
study indicated that sorafenib plus interferon was well tol-
erated [22]; furthermore, sorafenib plus interferon, either
as first- or second-line treatment for advanced RCC pro-
duced substantial activity in patients with advanced RCC,
as reported in two phase II trials [23,24]. However, com-
parison of patients treated with or without interferon in
our series is not feasible as the number of patients was
limited. We consider the non-protocolized treatment with
Overall survival of patients Figure 2
Overall survival of patients.BMC Cancer 2009, 9:249 http://www.biomedcentral.com/1471-2407/9/249
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cytokine in this small portion of patients as well as the
design of the study (i.e., non-phase-II trial) served as two
pitfalls of our series.
Multivariate analyses of the current study showed that
ECOG, presence of lymph node metastasis (N+), and use
of nephrectomy during the course of treatment were sig-
nificant predictive factors for disease control by sorafenib.
Although favorable ECOG status may assure better toler-
ance to the treatment, the association of nodal metastasis
and use of nephrectomy to improved response to soraf-
enib requires further discussion. Results from preclinical
studies have indicated that VEGFR is associated with
hematogenous metastasis in renal cell carcinoma [25,26],
and tumor metastasis via lymphatics can be inhibited by
interference with the VEGF-C VEGFR3 interaction [27]. It
is possible that the postulated targets of sorafenib such as
VEGFR are also associated to nodal metastasis in RCC.
However, further investigation is needed to confirm such
association. Furthermore, nephrectomy followed by Inter-
feron Alfa-2b was associated with significant improve-
ment in medial survival as compared to those treated with
interferon alone, and the median survival were 11.1
months versus 8.1 months for patients treated with or
Table 2: Cumulative incidence of toxicities
Toxicity grade
Sorafenib as First Line Treatment
(N = 59)
Sorafenib as Second Line Treatment
(N = 39)
Toxicity 1–2 3–4 1–2 3–4
Hand-foot syndrome 44 8 21 5
Alopecia 41 1 25 0
Rash 22 0 11 0
Mucositis (oral cavity) 11 1 5 0
Diarrhea 25 1 16 0
Hypertension 14 1 7 1
Fatigue & Anepithymia 41 1 30 2
Weight loss 6 0 3 0
Hemorrhage (nasal
mucocutaneous) 6 0 3 0
Anemia 7 1 5 0
Thrombocytopenia 0 0 1 0
Leukopenia 0 0 0 0
Hemorrhage (digestive tract) 0 1 1 2
Hematuria 4 0 0 0
Hemoptysis 8 1 4 1
Liver dysfunction 7 2 3 0
Angina 0 1 0 0
Table 3: Multivariate analysis
Predictive Factors CR+PR+SD PD Number (%) X2 P
Lymph node metastasis at initial diagnosis 4.69 0.030
N0 44(60.27) 29(39.73) 73(100.00)
N+ 21(84.00) 4(16.00) 25(100.00)
Nephrectomy before metastasis 8.05 0.005
No 15(46.88) 17(53.12) 32(100.00)
Yes 50(75.76) 16(24.24) 66(100.00)
ECOG 11.28 0.010
0 44(78.57) 12(21.43) 56(100.00)
1 20(54.05) 17(45.95) 37(100.00)
2 1 (25.00) 3(75.00) 4(100.00)
3 0(0.00) 1(100.00) 1(100.00)BMC Cancer 2009, 9:249 http://www.biomedcentral.com/1471-2407/9/249
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without nephrectomy [28]. However, the molecular basis
of the association between nephrectomy and improved
patients' prognoses is unknown. In the current study,
patients who had completed nephrectomy for definitive
treatment prior to the development of metastasis experi-
enced improved response to sorafenib, as compared to
those who received nephrectomy for their metastatic dis-
ease and those who did not receive surgery combined. In
other words, it appears that metastatic foci developed after
the resection of the primary disease responded to soraf-
enib better than those developed with the primary disease
intact. Although the clinical and molecular bases of the
findings in the multivariate analyses are unknown, these
results are important clinically and certainly warrant fur-
ther study for its root cause. Further investigation for
establishing a predictive model for individualizing soraf-
enib use in advanced RCC should also be considered.
The median PFS of our series was 60 weeks, and the
median OS was not reached. The underlying reason of this
seemingly more favorable outcome as compared to the
results of TARGET study and the phase II trial from Japan
is unknown at this time. The outcome between the three
studies cannot be compared directly; however, the magni-
tude of the discrepancy in PFS warrants further explora-
tion and confirmation. One potential explanation of such
discrepancy is the inherent differences between ethnic
Chinese and other ethnic groups. In a pooled safety anal-
ysis of sorafenib in the treatment of solid tumors includ-
ing RCC, severity of skin reaction and diarrhea was
significantly associated to time-to-progression [29]. It is
interesting to note that the probabilities of hand-foot skin
reaction (HFSR) in our series and in the sorafenib Asian-
Pacific trail on hepatocellular carcinoma were substan-
tially higher [30], as compared to the TARGET study and
the European SHARP trail [7,31]. It seems that Asian par-
ticularly Chinese patients are more prone to HFSR caused
by sorafenib. However, whether the ethnic background
and its associated molecular mechanism serves the major
difference in the efficacy of sorafenib in RCC subject to
further investigation. Furthermore, since sorafenib was
used as a first-line treatment in the majority of our
patients, with or without concurrent cytokine treatment.
Whether timing for the delivery of medication had
affected the treatment outcome in Chinese patients
should be considered. In addition, as the exact mecha-
nism of sorafenib on RCC remains unknown, investiga-
tion of any phenotypic variations is currently not feasible.
One of the possible solutions is to utilize gene-profiling
technology to detect the differences between patients with
different response to the treatment. In the participating
hospitals of the current study, tumor tissues from patients
accrued have been harvested and stored for a parallel
study under planning.
Conclusion
Sorafenib was efficacious in the treatment of metastatic
renal cell carcinoma in Chinese patients, and was well tol-
erated. The median progression-free survival time was 60
weeks, and overall survival time was not reached after a
follow-up of 76 weeks. Multivariate analyses revealed that
favorable ECOG status, presence of lymph node metasta-
sis, and nephrectomy prior to the development of metas-
tasis were significant predictive factors of tumor response
to sorafenib.
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